Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults (RBL)

Gachon University Gil Medical Center

Status: Completed

Conditions: High-grade B-cell Lymphoma; Burkitt's Lymphoma

Treatments: Other: No intervention (observational study)

Study type: Observational

Funder types: Other

Identifiers

NCT01809600

CISL-1203

Details and patient eligibility

About

This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.

Full description

Inclusion criteria

1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria
2. age >20 yrs
3. received rituximab+chemotherapy as first-line treatment
4. with measurable or evaluable lesion
5. with complete set of clinical and laboratory data for the analysis

Enrollment: 43 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria
2. age >20 yrs
3. received rituximab+chemotherapy as first-line treatment
4. with measurable or evaluable lesion

Exclusion criteria

1. patients with BL or BL-U previously treated with rituximab

Trial design

43 participants in 1 patient group

Patients with Burkitt's Lymphoma

Description:

should be diagnosed pathologically by WHO 2008 criteria

Treatment:

Other: No intervention (observational study)